Hangzhou Bio-Sincerity Pharma-TechLtd Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Jinfang Lou
Chief executive officer
CN¥2.1m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 9yrs |
| CEO ownership | 12.5% |
| Management average tenure | 2.9yrs |
| Board average tenure | 5.9yrs |
Recent management updates
Recent updates
We Believe That Hangzhou Bio-Sincerity Pharma-TechLtd's (SZSE:301096) Weak Earnings Are A Good Indicator Of Underlying Profitability
Nov 04
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE:301096) Soars 30% But It's A Story Of Risk Vs Reward
Sep 30Market Cool On Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s (SZSE:301096) Earnings Pushing Shares 27% Lower
Jul 24Solid Earnings May Not Tell The Whole Story For Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096)
Apr 29Should You Be Adding Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096) To Your Watchlist Today?
Mar 14CEO
Jinfang Lou (56 yo)
9yrs
Tenure
CN¥2,052,600
Compensation
Ms. Lou Jinfang is Chairwoman of the Board of Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. from December 15, 2015.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairwoman of the Board & GM | 9yrs | CN¥2.05m | 12.46% CN¥ 536.5m | |
| Chief Financial Officer & Accounting Supervisor | 1.8yrs | CN¥453.10k | 0.0047% CN¥ 201.1k | |
| Deputy GM & Director | 6yrs | CN¥1.05m | 0.045% CN¥ 1.9m | |
| Deputy GM | 1.8yrs | CN¥712.60k | 0.011% CN¥ 491.3k | |
| Deputy General Manager | 2.9yrs | CN¥902.30k | 0.041% CN¥ 1.8m | |
| Deputy General Manager | 6yrs | CN¥1.01m | 0.047% CN¥ 2.0m | |
| Deputy General Manager | 2.9yrs | CN¥897.00k | 0.022% CN¥ 952.8k |
2.9yrs
Average Tenure
43yo
Average Age
Experienced Management: 301096's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairwoman of the Board & GM | 9yrs | CN¥2.05m | 12.46% CN¥ 536.5m | |
| Deputy GM & Director | 6yrs | CN¥1.05m | 0.045% CN¥ 1.9m | |
| Deputy GM | 6yrs | CN¥712.60k | 0.011% CN¥ 491.3k | |
| Deputy Chairman of the Board | 6yrs | CN¥1.56m | 18.69% CN¥ 804.5m | |
| Independent Director | 5.5yrs | CN¥100.00k | no data | |
| Director | 2.9yrs | CN¥802.50k | 0.0086% CN¥ 370.7k | |
| Supervisor | 5.8yrs | no data | no data | |
| Director | 1.8yrs | CN¥1.07m | 0.035% CN¥ 1.5m |
5.9yrs
Average Tenure
46.5yo
Average Age
Experienced Board: 301096's board of directors are considered experienced (5.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 06:27 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiabo Zhang | Guosen Securities Co., Ltd. |
| Yuan Yuan Sun | Industrial Securities Co. Ltd. |
| Chaoze Zhou | Minsheng Securities Co. |